Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

he Phase 2b with Roche in second half of 2009;
  • Report phase 1 antiviral data with PSI-7851 in second half of 2009;
  • Report further data from INFORM-1 trial in fourth quarter of 2009.

  • About Pharmasset

    Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

    Pegasys(R) and Copegus(R) are registered trademarks of Roche.

        Contact
        Richard E. T. Smith, Ph.D.
        VP, Investor Relations and Corporate Communications
        richard.smith@pharmasset.com
        Office: +1 (609) 613-4181
    

    Forward-Looking Statements

    Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
    3. Pharmasset Accesses up to $30 Million of Working Capital
    4. Pharmasset to Present at Three Investor Conferences in November 2007
    5. Pharmasset Appoints Michael Rogers as Chief Development Officer
    6. Pharmasset Reports Fiscal Year End 2007 Financial Results
    7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
    8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
    9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
    10. Pharmasset Appoints Herbert J. Conrad as a Director
    11. Pharmasset Receives $10 Million of Working Capital
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ... revenue and share analysis. , Full Copy ...
    (Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this ... James L. Sherley, director of the Adult Stem Cell ... an often overlooked and under appreciated unique property of ... by Distributed Stem Cells: Misunderstood in the Past, Important ... to congress participants. He gave the address at ...
    (Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
    (Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
    Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
    ... CITY, March 26 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today reported ... the Company,s lead luteinizing,hormone-releasing hormone (LHRH) antagonist, in ... in benign prostatic hyperplasia (BPH), a,non-cancerous enlargement of ...
    ... (Amex:,ECI) ("Encision" or the "Company") announced today that ... for its AEM(R) articulating laparoscopic,instrument inserts., The ... shaft design to,accommodate the stresses generated by organ ... In addition, the new, easy to,operate rotation knob ...
    ... (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ),the global specialty biopharmaceutical company, announces the release on,March 25, ... with the Shire Long Term Incentive Plan ("LTIP")., In accordance with the rules ... ... ...
    Cached Biology Technology:Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia 2Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia 3Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia 4Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures 2Shire plc: Long Term Incentive Plan 2
    (Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may ... as Acuity Market Intelligence reports that the long ... open. Acuity forecasts that intensifying demand for smart ... biometrics will drive a global market of 2.5 ... by 2020.   According to ...
    (Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
    (Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
    Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
    ... PASADENA, Calif.Our belief as to whether we will likely succeed ... or losingdirectly affects the levels of neural effort put forth ... new brain-imaging study by neuroscientists at the California Institute of ... Richard A. Andersen, the James G. Boswell Professor of Neuroscience ...
    ... ASHEVILLE, NC USDA Forest Service Southern Research ... foresters, landowners and others concerned about nonnative invasive plants ... "A Field Guide for the Identification of Invasive Plants ... of the very popular "Nonnative Invasive Plants of Southern ...
    ... A unique blob-like creature that lived in the ocean approximately ... model in research published today in the journal Biology ... primitive species on early Earth looked like and how they ... on Earth today. The scientists, from Imperial ...
    Cached Biology News:Caltech: Gain and loss in optimistic versus pessimistic brains 2Caltech: Gain and loss in optimistic versus pessimistic brains 3Forest Service updates free guide to 'Invasive Plants in Southern Forests' 2Ancient blob-like creature of the deep revealed by scientists 2
    ... KGaA. Physical form: Solution in 50% glycerol containing 20 ... , and 20 mM NaCl Preparation Unit Definition: One ... oligonucleotides equivalent to a ΔA 260 of 1.0 ... (reaction volume 2.625 ml). Assay: SDS-PAGE ≥ 90 ...
    ... Immunoassay Stabilizer is an aqueous solution that ... non-toxic chemicals in a PBS buffer (phosphate ... This product does not contain a preservative. ... and activity of dried protein components in ...
    ... StabilZyme NOBLE BSA-Free Stabilizer is a ... Stabilizer. It is an aqueous ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic ... contains a combination of 0.02% methylisothiazolone ...
    Mouse monoclonal antibody to PARK2 - Parkinson disease (autosomal recessive, juvenile) 2, parkin...
    Biology Products: